Phase 1 × Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all
NCT02924402 2024-11-13

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Xencor, Inc.

Phase 1 Completed
154 enrolled
NCT03833180 2024-01-12

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Completed
91 enrolled
NCT01523223 2023-11-22

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Stanford University

Phase 1 Completed
16 enrolled
NCT00443976 2023-08-04

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Canadian Cancer Trials Group

Phase 1 Completed
35 enrolled
NCT02890758 2023-02-21

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
286 enrolled 26 charts